Strategic Value Inflections

Selected Experience

Judgment carries more weight when it has been tested in the operating seat.

SVI's perspective is grounded in executive responsibility across pharmaceuticals, biotechnology, diagnostics, nuclear medicine, regulatory, and medical devices. Experience includes transactions, P&L ownership, R&D, regulatory, commercialization, manufacturing considerations, market access, portfolio strategy, and operating transformation.

Transaction and portfolio leadership

$10.4B+ in acquisitions and portfolio activity

Senior corporate development leadership at a global specialty pharmaceutical company, across strategic assessments, acquisitions, divestitures, partnerships, alliances, and portfolio transformation.

Oncology

From strategy through development and commercialization

Experience building oncology growth platforms, advancing development programs and clinical trials, leading cross-functional teams, developing companion diagnostic strategies, and forming external alliances.

Radiopharmaceuticals and nuclear medicine

Experience across development, operations, supply, and commercialization

Experience includes nuclear medicine and radiopharmaceutical R&D, manufacturing considerations, supply and logistics, regulatory compliance, commercialization, portfolio strategy, and operating economics. This experience provides a perspective that extends beyond clinical opportunity into the practical requirements needed to deliver that opportunity reliably and at scale.

Medical devices

Strategy translated into transaction and operating value

Senior corporate-strategy leadership for a $1.2B pharmaceutical and medical device business, including origination of the strategic case behind a $2.6B peripheral vascular medical device transaction.

Diagnostics

Commercial growth, market access, and transaction experience

At a point-of-care diagnostics company, commercial restructuring preceded significant revenue growth and a successful sale process. At a global in vitro diagnostics company, commercial-model and distributor changes supported renewed growth and profitability across North and Latin America. Created and implemented healthcare economics programs to support reimbursement and adoption.

Market access

Payer strategy with operating consequences

Earlier diagnostics leadership included integrated-health-system, GPO, and disease-management programs associated with more than $100M of new revenue.

CEO leadership

Responsibility beyond the recommendation

As CEO of an early-stage immuno-oncology company, led corporate strategy, R&D and clinical direction, regulatory planning, and partnerships.

SVI advisory work

Strategic Value Inflections has supported strategy and portfolio decisions, buy-side and sell-side work, valuation and diligence, market access, commercialization, capital strategy, and strategic alliances for life-sciences companies and investors.

Confidentiality: All of SVI's advisory work is confidential. Client-specific examples are shared only where appropriate and authorized.

Work with SVI

The best read on a deal starts before the LOI.

Schedule a conversation →